This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
The implications of the new HCV guidance for all clinicians are discussed by Paul Martin, MD (member of the writing panel), and Helen Boucher, MD, in an interview with Medscape.
Drs. Paul Sax and David Thomas reflect on how the worlds of gastroenterology and infectious disease have joined to meet the need for fast-paced guidance in hepatitis C treatment.
About 2.7 million US residents in the population sampled by NHANES 2003-2010 have chronic HCV infection, which is about 500,000 fewer than a similar estimate for 1999-2002.
No comments:
Post a Comment